Lexicon Pharmaceuticals (LXRX) Receivables (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Receivables of $11.8 million for Q1 2026, down 75.17% year-over-year from $47.4 million in Q1 2025, and up 394.09% quarter-over-quarter from $2.4 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Receivables (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Receivables for 17 consecutive years, with $11.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 75.17% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $11.8 million (down 75.17% YoY), while the FY2025 annual figure was $2.4 million, down 31.36% from the prior year.
- Receivables improved to $11.8 million in Q1 2026 per LXRX's latest filing, from $2.4 million in the prior quarter.
- Across five years, Receivables topped out at $47.4 million in Q1 2025 and bottomed at $28000.0 in Q4 2022.
- Historically, Receivables has averaged $4.7 million across 5 years, with a median of $1.5 million in 2024.
- Annual changes were most pronounced in 2022 — Receivables tumbled 78.62% — and 2023, when it jumped 3507.14%.
- Lexicon Pharmaceuticals' Receivables stood at $28000.0 in 2022, then surged by 3507.14% to $1.0 million in 2023, then soared by 243.86% to $3.5 million in 2024, then tumbled by 31.36% to $2.4 million in 2025, then surged by 394.09% to $11.8 million in 2026.
- Business Quant data shows LXRX's Receivables at $11.8 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Mn |
| Mar 31, 2026 | 11.78 Mn |
| Dec 31, 2025 | 2.38 Mn |
| Sep 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.18 Mn |
| Mar 31, 2025 | 47.45 Mn |
| Dec 31, 2024 | 3.47 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.62 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 318,000.00 |
| Jun 30, 2023 | 685,000.00 |
| Mar 31, 2023 | 261,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 34,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | 14,000.00 |
| Sep 30, 2021 | 23,000.00 |